Literature DB >> 30889975

Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland.

Danielle Leighton1,2,3,4, Judith Newton1,2,3, Shuna Colville1,2,3, Andrew Bethell5, Gillian Craig6, Laura Cunningham4,7, Moira Flett8, Dianne Fraser9, Janice Hatrick4, Helen Lennox10,11, Laura Marshall12, Dympna McAleer6, Alison McEleney3,13, Kitty Millar14, Ann Silver4,7, Laura Stephenson2,3, Susan Stewart9, Dorothy Storey15, Gill Stott3,13, Carol Thornton9, Carolyn Webber6, Harry Gordon1,2,3, Giulia Melchiorre1,2,3, Laura Sherlock1,2, Emily Beswick1,2, David Buchanan1,2, Sharon Abrahams1,2,3, Anthony Bateman1,2,3, Jenny Preston10, Callum Duncan9, Richard Davenport1,2,3, George Gorrie2,4, Ian Morrison6, Robert Swingler1,2, Siddharthan Chandran1,2,3, Suvankar Pal1,2,3,12.   

Abstract

Objectives: Launched in 1989, the Scottish Motor Neuron Disease Register (SMNDR) has provided a resource for prospective clinical data collection. However, in 2015 we aimed to evolve a system to allow: i) A patient-centered approach to care based on recognized standards, ii) Harmonized data sharing between Scottish health professionals in "real-time", iii) Regular audit of care to facilitate timely improvements in service delivery, and iv) Patient participation in a diverse range of observational and interventional research studies including clinical trials.
Methods: We developed a standardized national electronic data platform-Clinical Audit Research and Evaluation of MND (CARE-MND) which integrates clinical audit and research data fields. Data completion pre- and post-CARE-MND were compared, guided by recently published National Institute for Clinical Excellence (NICE) recommendations. Statistical difference in data capture between time periods was assessed using Z-test of proportions.
Results: Data field completion for the historical 2011-2014 period ranged from 4 to 95%; median 50%. CARE-MND capture ranged from 32 to 98%; median 87%. 15/17 fields were significantly more complete post-CARE-MND (p < 0.001). All MND nurse/allied health specialists in Scotland use the CARE-MND platform. Management of MND in Scotland is now coordinated through a standardized template. Conclusions: Through CARE-MND, national audits of MND care and interventions have been possible, leading to protocols for harmonized service provision. Stratification of the MND population is facilitating participation in observational and interventional studies. CARE-MND can act as a template for other neurological disorders.

Entities:  

Mesh:

Year:  2019        PMID: 30889975     DOI: 10.1080/21678421.2019.1582673

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  6 in total

1.  Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis.

Authors:  Arpan R Mehta; Jenna M Gregory; Owen Dando; Roderick N Carter; Karen Burr; Jyoti Nanda; David Story; Karina McDade; Colin Smith; Nicholas M Morton; Don J Mahad; Giles E Hardingham; Siddharthan Chandran; Bhuvaneish T Selvaraj
Journal:  Acta Neuropathol       Date:  2021-01-04       Impact factor: 17.088

2.  National audit of cognitive assessment in people with pwMND A national audit of cognitive assessment in people with motor neurone disease (pwMND) in Scotland.

Authors:  Maria Stavrou; Judith Newton; Gill Stott; Shuna Colville; Siddharthan Chandran; Sharon Abrahams; Suvankar Pal; Richard Davenport
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-04-20       Impact factor: 4.092

3.  The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland.

Authors:  Stella A Glasmacher; Juan Larraz; Arpan R Mehta; Patrick K A Kearns; Michael Wong; Judith Newton; Richard Davenport; George Gorrie; Ian Morrison; Javier Carod Artal; Siddharthan Chandran; Suvankar Pal
Journal:  J Neurol       Date:  2020-09-05       Impact factor: 4.849

4.  Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.

Authors:  Emily Beswick; Stella A Glasmacher; Rachel Dakin; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  BMJ Open       Date:  2021-03-23       Impact factor: 2.692

Review 5.  Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective.

Authors:  Charis Wong; Maria Stavrou; Elizabeth Elliott; Jenna M Gregory; Nigel Leigh; Ashwin A Pinto; Timothy L Williams; Jeremy Chataway; Robert Swingler; Mahesh K B Parmar; Nigel Stallard; Christopher J Weir; Richard A Parker; Amina Chaouch; Hisham Hamdalla; John Ealing; George Gorrie; Ian Morrison; Callum Duncan; Peter Connelly; Francisco Javier Carod-Artal; Richard Davenport; Pablo Garcia Reitboeck; Aleksandar Radunovic; Venkataramanan Srinivasan; Jenny Preston; Arpan R Mehta; Danielle Leighton; Stella Glasmacher; Emily Beswick; Jill Williamson; Amy Stenson; Christine Weaver; Judith Newton; Dawn Lyle; Rachel Dakin; Malcolm Macleod; Suvankar Pal; Siddharthan Chandran
Journal:  Brain Commun       Date:  2021-10-23

6.  Improved detection of RNA foci in C9orf72 amyotrophic lateral sclerosis post-mortem tissue using BaseScope™ shows a lack of association with cognitive dysfunction.

Authors:  Arpan R Mehta; Bhuvaneish T Selvaraj; Samantha K Barton; Karina McDade; Sharon Abrahams; Siddharthan Chandran; Colin Smith; Jenna M Gregory
Journal:  Brain Commun       Date:  2020-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.